GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

XORTX Therapeutics XRTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.85

-7.14%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About XORTX Therapeutics

Its shares trade under the ticker XRTX. It has been listed since 28 November 2018.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Nov 2018
Employees
2
Website
xortx.com ↗
Head office
SUITE 2400 - 745 THURLOW STREET, VANCOUVER, A1, V6E 0C5
Incorporated in
A1
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • XORTX Therapeutics Inc operates in the Health Care sector with specialized drug programs.
  • The company has two employees focusing on late-stage clinical pharmaceutical development.
  • XRx-026 is currently in Phase III trials for treating gout patients effectively.

Weaknesses

  • The firm relies on only two employees to manage complex clinical operations.
  • XORTX Therapeutics Inc is listed on the market since November 2018.
  • Resources are limited for developing multiple pipeline assets simultaneously across phases.

Opportunities

  • XRx-008 targets autosomal dominant polycystic kidney disease in Phase II trials.
  • XRx-101 addresses acute kidney injury associated with respiratory virus infections like sepsis.
  • VB4-P5 offers potential for treating and preventing fibrosis in the kidney.

Threats

  • XRX-225 remains in the preclinical stage for type 2 diabetic nephropathy.
  • Regulatory hurdles may delay the commercialization of therapies in Canada.
  • Competition in the Health Care sector could impact market adoption rates.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.